Lipid Nanoparticles CDMO Market to Witness Double-Digit Growth by 2027
The global lipid nanoparticles (LNP) contract development and manufacturing organization (CDMO) market is poised for substantial double-digit growth by 2027, driven by the growing acceptance of LNPs in mRNA therapeutics, a strong pipeline of LNP-related drugs, and aggressive investments by private equity firms in the lipid nanoparticle CDMO space.
Lipid nanoparticles are innovative spherical vesicles composed of ionizable lipids that play a pivotal role in effectively protecting and delivering mRNA into cells. Their application as advanced drug delivery vehicles has significantly expanded in recent years, positioning them as crucial enablers for next-generation vaccines and therapeutics.
Global Lipid Nanoparticles CDMO Market is Driven by Rising Demand for mRNA Therapeutics, Strong Pipeline of LNP-Based Drugs, and Strategic Private Equity Investments
Explore market trends, size, share and growth report - request a sample copy: https://meditechinsights.com/lipid-nanoparticles-cdmo-market/request-sample/
LNPs Fuel COVID-19 Vaccine Success and Accelerate Market Demand
The emergence of COVID-19 highlighted the vital role of lipid nanoparticles in mRNA vaccine delivery. Lipids, as essential molecules within living cells, surround the mRNA to form lipid nanoparticles, safeguarding the genetic material from degradation while ensuring targeted delivery into cells.
“The effectiveness of mRNA vaccines against COVID-19 bolstered the demand for lipid nanoparticle (LNP)-mediated drug delivery for RNA vaccines and therapeutics. As projects entered the commercialization stage from clinical trials, developers faced challenges in maintaining consistency in LNP formulation to meet the rising demand,” stated a Senior Scientist at a leading U.S.-based Lipid Nanoparticle CDMO.
This widespread acceptance and proven efficacy of LNP-based drug delivery has catalyzed growth in the global lipid nanoparticles CDMO market, as pharmaceutical companies increasingly seek reliable CDMO partners to support scalable and compliant production.
Strong Pipeline of LNP-Related Drugs Spurs Market Expansion
Lipid nanoparticles possess the unique capability to deliver unstable genetic materials such as mRNA, siRNA, and gene therapies into cells while ensuring protection and stability. Currently, more than 2,000 LNP-related pipeline drugs are under development globally, spanning areas such as oncology, infectious diseases, and genetic disorders.
This growing pipeline is expected to significantly drive demand for contract manufacturing services to support clinical trials and large-scale commercial production. Recognizing this growth opportunity, leading CDMO players are adopting strategic partnerships, capacity expansions, and acquisitions to strengthen their market position.
For example, in May 2023, Inventage Lab entered into a co-development and manufacturing commercialization agreement with EuBiologics to accelerate LNP production capabilities for pipeline and commercialized products.
Private Equity Investments Accelerate Lipid Nanoparticles CDMO Market Growth
Private equity firms are increasingly investing in lipid nanoparticle CDMOs, attracted by their strong growth potential and essential role in next-generation drug delivery technologies.
In June 2023, Vernal Biosciences, an mRNA and LNP CDMO, completed a $20 million funding round led by Ampersand Capital Partners and Charles River Labs, with participation from Dynamk Capital and the Vermont Center for Emerging Technologies, to expand its GMP mRNA and LNP manufacturing capacities.
In August 2022, Phosphorex, a drug delivery-focused CDMO specializing in microspheres and polymer and lipid nanoparticles, announced a majority recapitalization by Ampersand Capital Partners, further solidifying its position to meet growing market needs.
Competitive Landscape: Key Players Strengthening Market Foothold
Prominent players operating in the global lipid nanoparticles CDMO market include:
- Evonik Health Care
- Merck
- CordenPharma
- Phosphorex
- eTheRNA Manufacturing
- Fujifilm Pharmaceuticals
- Helix Biotech
- BIOVECTRA
- Vernal Biosciences
These players are adopting organic and inorganic strategies such as facility expansions, strategic acquisitions, and development partnerships to enhance their manufacturing capabilities and accelerate market penetration.
Explore the latest trends and competitive landscape analysis: https://meditechinsights.com/lipid-nanoparticles-cdmo-market/request-sample/
Recent Strategic Developments:
- March 2023: Evonik inaugurated new facilities in Lafayette, Indiana (USA) and Hanau (Germany) to expand its pharmaceutical lipid production capacity.
- March 2022: CordenPharma increased its lipid manufacturing capacity to support the production of mRNA vaccines.
- January 2022: Merck signed a definitive agreement to acquire Exelead, a full-service CDMO focused on LNP formulations, strengthening its mRNA and lipid manufacturing capabilities.
- December 2021: WACKER and CordenPharma entered a development partnership to jointly advance know-how and processes for LNP manufacturing to meet growing global demand.
Outlook: Expanding Applications to Drive Future Market Growth
The lipid nanoparticles CDMO market is expected to maintain consistent momentum in the coming years due to the expanding application of lipid nanoparticles across diverse therapeutic areas including vaccines, oncology treatments, gene therapies, and rare disease therapeutics. The versatility of LNPs in effectively delivering genetic materials to target cells with high precision continues to drive innovation and investment in this sector.
Additionally, increasing R&D expenditure by pharmaceutical companies and growing government support for advanced drug delivery systems are further expected to propel market growth. Strategic collaborations, facility upgrades, and robust pipeline developments remain key focus areas for CDMO players aiming to capitalize on the immense market potential.
Partner with Leading LNP CDMO Providers for Scalable and Compliant Production
Companies aiming to accelerate their mRNA-based therapeutics, vaccines, and gene therapies are increasingly seeking specialized lipid nanoparticle CDMO partners to ensure quality, regulatory compliance, and scalability from preclinical to commercial manufacturing.
To explore strategic partnerships and contract manufacturing opportunities in the growing lipid nanoparticles CDMO market, connect with global leaders today and leverage their expertise to fast-track your innovative therapeutics to market.
Latest Healthcare & Pharma Industry Research Reports
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
Phone: +32 498 86 80 79
Email: info@meditechinsights.com
Website: https://meditechinsights.com/
Editor Details
-
Company:
- Medi-Tech Insights
-
Name:
- Ram Sonagara
- Email:
-
Telephone:
- +32498868079
- Website:
Related Links
- Website: Lipid Nanoparticles CDMO
